Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Androgenetic Alopecia: early-phase trial registry
3 of 18 indexed Androgenetic Alopecia trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #953 of 28,707 conditions by registered trial count.
18 US clinical trials · 3 currently recruiting · #953 of 28,707 conditions by registered trial count
Androgenetic Alopecia: 18 US clinical trials tracked, 3 recruiting.
Androgenetic Alopecia is the subject of 18 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most active sponsor is Veradermics, running 4 of these trials.
Enrollment posture brief
Registry condition androgenetic-alopecia
OPEN 3 | RECR 17% | LATE 3 | EARLY 7 | RANK #953 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Acute Renal Failure (17% recruiting · 6 trials)
Androgenetic Alopecia lists 3 open slots (17% of 18 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Androgenetic Alopecia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Androgenetic Alopecia is recruiting below its size-band peers.
3 of 18 indexed trials (16.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Androgenetic Alopecia research.
Veradermics accounts for 4 of 18 trials (22.2%). 15 distinct sponsors appear on at least one study for this condition label.
-
Most Androgenetic Alopecia trials plan to enrol fewer than 100 people.
Median target enrolment is 49 among the 17 trials that report a genuine target (sentinel values excluded). 12 of those (70.6%) plan for fewer than 100 participants.
-
Androgenetic Alopecia research is mostly interventional.
17 interventional and 1 observational studies make up this index (94.4% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
18 total, page 1 of 1
Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA)
Veradermics
NCT07146022
Sham LaserCap vs. LaserCap SD vs. LaserCap HD+
University of Arizona
NCT05365360
1470nm Laser for the Treatment of Androgenetic Alopecia and Scarring Alopecia
Montefiore Medical Center
NCT05460611
Efficacy and Safety of VDPHL01 in Males With AGA
Veradermics
NCT06724614
Safety and Efficacy of VDPHL01 in Males With AGA
Veradermics
NCT06972264
Safety and Efficacy of VDPHL01 in Males and Females With AGA
Veradermics
NCT06527365
Use of Botulinum Toxin in the Treatment of Androgenic Alopecia
Zel Skin and Laser Specialists
NCT05456087
A Study to Evaluate the Effectiveness and Safety of 5 Percent Minoxidil Foam in the Treatment of Male Pattern Hair Loss
Johnson & Johnson Consumer and Personal Products Worldwide
NCT00151515
Minoxidil Response Testing in Males With Androgenetic Alopecia
Applied Biology
NCT02198261
Safety, Pharmacokinetics and Efficacy of PP405 in Adults With AGA
Pelage Pharmaceuticals
NCT06393452
A Study of SM04554 Applied Topically to the Scalp of Male Subjects With Androgenetic Alopecia Analyzed by Biopsy of the Scalp Prior To and Post Dosing
Biosplice Therapeutics
NCT02503137
A Study Evaluating the Hair Regrowth Efficacy and Safety of ALRV5XR in Female Subjects With Hair Loss
Arbor Life Labs
NCT04450602
Computer-Assisted Versus Manual Hair Harvest Comparative Study
Restoration Robotics
NCT00926211
A Study to Evaluate and Compare Injections of Autologous Mixed Population of Dermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004542)
Aderans Research Institute
NCT01451151
A Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical Solution
Aclaris Therapeutics
NCT03495817
The Effect of Platelet Rich Plasma on Non-scarring Alopecia
Icahn School of Medicine at Mount Sinai
NCT03689452
Penetration-enhanced Direct DBD Non-thermal Plasma for Hair Loss
Dr. Peter C. Friedman
NCT06149221
A Randomized, Double-blind Clinical Trial to Evaluate the Safety and Efficacy of the X5 HairLaser for the Treatment of Androgenetic Alopecia in Males
Spencer Forrest
NCT02067260
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 7 |
| Phase 3 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Androgenetic Alopecia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Androgenetic Alopecia trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Androgenetic Alopecia page
18 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Androgenetic Alopecia trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Veradermics sponsors the most Androgenetic Alopecia trials on record, review their full trial history before evaluating a specific study. See Veradermics's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Androgenetic Alopecia condition card totals 18 registered trials; most-linked intervention VDPHL01; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.